Cadila Healthcare rises on launching world’s first bio-similar of Adalimumab

10 Dec 2014 Evaluate

Cadila Healthcare is currently trading at Rs. 1601.10, up by 25.05 points or 1.59 % from its previous closing of Rs. 1576.05 on the BSE.

The scrip opened at Rs. 1584.35 and has touched a high and low of Rs. 1618.90 and Rs. 1579.40 respectively. So far 4669 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1760.00 on 11-Nov-2014 and a 52 week low of Rs. 723.10 on 11-Dec-2013.

Last one week high and low of the scrip stood at Rs. 1694.00 and Rs. 1559.20 respectively. The current market cap of the company is Rs. 32821.19 crore.

The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 14.51 % and 10.69 % respectively.

Zydus Cadila (Cadila Healthcare ) has launched the bio-similar of Adalimumab -the world's largest selling therapy. Bio-similar, developed by the researchers at the Zydus Research Centre, has been approved by the Drug Controller General of India and will be marketed under the brand name, ‘Exemptia’ to treat auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and Ankylosing  Spondylitis.

This novel non-infringing process for Adalimumab and a novel non-infringing formulation has been researched, developed and produced by scientists at the Zydus Research Centre. The biosimilar is the first to be launched by any company in the world and is a fingerprint match with the originator in terms of safety, purity and potency of the product. The biosimilar of Adalimumab is a part of Zydus' robust biologics programme which has the largest number of monoclonal antibodies under development in India. The group's R&D pipeline which comprises 24 biologics includes biosimilars and three novel biologics. These biologics are being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.

Adalimumab, the fully human anti-TNF alpha monoclonal antibody, was first approved globally in 2002 and has since then been the most preferred therapy to treat patients suffering from auto immune disorders. However, the therapy was not available to patients in India.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×